On May 29, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective medicines to treat a wide range of cancers, reported that Drew Fromkin, President and Chief Executive Officer, will present at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA (Press release, Tarveda Therapeutics, MAY 29, 2018, View Source [SID1234526929]). The presentation will take place on Tuesday, June 5, 2018 at 11:00 AM ET in Theatre 1 within the Boston Convention & Exhibition Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Fromkin will provide an overview of the company’s Pentarin platform with a focus on its clinical stage drug candidates, PEN-221 and PEN-866. PEN-221 is currently being studied in the Phase 2a portion of a Phase 1/2a trial in patients with small cell lung cancer as well as GI-midgut and pancreatic neuroendocrine tumors that express somatostatin receptor 2 (SSTR2). PEN-866 recently entered into the Phase 1 portion of a Phase 1/2a trial to assess safety and efficacy across a range of tumor types.
To schedule a meeting with Tarveda’s management team at the Convention, please submit a meeting request through the BIO One-on-One Partnering system or contact [email protected].
About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.